Delay and inequalities in the treatment of idiopathic pulmonary fibrosis: the case of two Nordic countries

Delay and inequalities in the treatment of idiopathic pulmonary fibrosis: the case of two Nordic countries

Abstract Background Idiopathic pulmonary fibrosis (IPF) is characterized by progressive loss of lung function with high mortality within the first 5 years from diagnosis. In 2011–2014, two drugs, pirfenidone and nintedanib, have been approved worldwide for prevention of IPF progression. National IPF...

Full description

Bibliographic Details
Main Authors: Ida Pesonen, Lisa Carlson, Nicola Murgia, Riitta Kaarteenaho, Carl Magnus Sköld, Marjukka Myllärniemi, Giovanni Ferrara
Format: Article
Language:English
Published: PAGEPress Publications 2018-05-01
Series:Multidisciplinary Respiratory Medicine
Subjects:
Idiopathic pulmonary fibrosis
Interstitial lung disease
Nintedanib
Pirfenidone
Access to healthcare
Online Access:http://link.springer.com/article/10.1186/s40248-018-0126-7

Internet

http://link.springer.com/article/10.1186/s40248-018-0126-7

Similar Items